Ken Griffin Unity Biotechnology, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.4 - $4.27 $9,066 - $96,788	22,667 Added 25.0%	113,331 $45,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.29 $17,964 - $41,381	32,079 Added 54.76%	90,664 $51,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $29,691 - $76,702	-41,238 Reduced 41.31%	58,585 $66,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $100,469 - $244,990	77,284 Added 342.89%	99,823 $145,000
Q3 2021 Nov 15, 2021	SELL	$2.91 - $4.5 $86,325 - $133,492	-29,665 Reduced 56.83%	22,539 $67,000
Q2 2021 Aug 16, 2021	SELL	$4.15 - $6.3 $216,480 - $328,633	-52,164 Reduced 49.98%	52,204 $242,000
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $310,967 - $531,636	56,437 Added 117.75%	104,368 $627,000
Q4 2020 Feb 16, 2021	BUY	$3.42 - $6.36 $45,506 - $84,626	13,306 Added 38.43%	47,931 $251,000
Q3 2020 Nov 16, 2020	SELL	$2.94 - $12.43 $308,282 - $1.3 Million	-104,858 Reduced 75.18%	34,625 $120,000
Q2 2020 Aug 14, 2020	SELL	$5.28 - $9.67 $294,280 - $538,957	-55,735 Reduced 28.55%	139,483 $1.21 Million
Q1 2020 May 15, 2020	SELL	$5.0 - $7.6 $856,975 - $1.3 Million	-171,395 Reduced 46.75%	195,218 $1.13 Million
Q4 2019 Feb 14, 2020	SELL	$5.99 - $8.38 $31,507 - $44,078	-5,260 Reduced 1.41%	366,613 $2.64 Million
Q3 2019 Nov 14, 2019	BUY	$5.62 - $9.63 $750,196 - $1.29 Million	133,487 Added 56.0%	371,873 $2.27 Million
Q2 2019 Aug 14, 2019	BUY	$7.59 - $10.21 $1.48 Million - $1.99 Million	194,965 Added 449.01%	238,386 $2.27 Million
Q1 2019 May 15, 2019	BUY	$7.65 - $16.66 $215,760 - $469,878	28,204 Added 185.35%	43,421 $0
Q2 2018 Aug 10, 2018	BUY	$12.76 - $16.94 $194,168 - $257,775	15,217 New	15,217 $0

Others Institutions Holding UBX

# of Institutions

Shares Held

4.41M

Call Options Held

Put Options Held

Empery Asset Management, LP New York, NY

4.41M
Shares

$6.49 Million
10.37% of portfolio

View Full List

About Unity Biotechnology, Inc.

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

More about UBX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account